Atara Biotherapeutics Inc
(NAS:ATRA)
$
10.28
-1.35 (-11.61%)
Market Cap: 58.33 Mil
Enterprise Value: 83.40 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 40/100 
Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2019 / 05:00PM GMT
Release Date Price:
$551.25
(+0.68%)
Maryana Ilya Breitman
Goldman Sachs Group Inc., Research Division - Research Analyst
Good morning. It is our pleasure to welcome Atara team. My name is Maryana Breitman, I'm an analyst here at Goldman Sachs. And from Atara, we have AJ Joshi, Chief Medical Officer. I have Utpal Koppikar, Chief Financial Officer; and Joe Newell, Chief Tech Op Officer. Thank you. Welcome.
Utpal Koppikar
Atara Biotherapeutics, Inc. - CFO
Thank you.
Manher Joshi
Atara Biotherapeutics, Inc. - Chief Medical Officer
Thank you.
Joseph Newell
Atara Biotherapeutics, Inc. - Executive VP & Chief Technical Operations Officer
Thank you.
Questions & Answers
Maryana Ilya Breitman
Goldman Sachs Group Inc., Research Division - Research Analyst
Let's recap a little. There's been a lot of changes at Atara. And we just learned that there's going to be major management changes. Could you talk a little bit about the process how that change is
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers